Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Current Deferred Revenue (2017 - 2025)

Acro Biomedical has reported Current Deferred Revenue over the past 9 years, most recently at $20000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $20000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $20000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $20000.0, changed 0.0%.
  • Current Deferred Revenue for Q4 2025 was $20000.0 at Acro Biomedical, roughly flat from $20000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ACBM hit a ceiling of $20000.0 in Q1 2021 and a floor of $20000.0 in Q1 2021.
  • Median Current Deferred Revenue over the past 5 years was $20000.0 (2021), compared with a mean of $20000.0.
  • Peak annual rise in Current Deferred Revenue hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Acro Biomedical's Current Deferred Revenue stood at $20000.0 in 2021, then changed by 0.0% to $20000.0 in 2022, then changed by 0.0% to $20000.0 in 2023, then changed by 0.0% to $20000.0 in 2024, then changed by 0.0% to $20000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $20000.0 (Q4 2025), $20000.0 (Q3 2025), and $20000.0 (Q2 2025) per Business Quant data.